Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials
Clinical Trials as Topic
Neoplasm Recurrence, Local
1) The median PFS from second complete remission is short. 2) A second response is rarely longer than the first even in this second CR population. 3) The number of patients with a second response longer than the first, or the proportion of patients remaining in complete remission at given time points could be evaluated as an outcome measure in future studies.